Licensing Chinese Drug Assets: The Development Work That Determines Their Value

Authored by

Ben Dudley
President and Chief Commercial Officer

Licensing Chinese Drug Assets: The Development Work That Determines Their Value

China has become one of the world’s most productive sources of new drug assets. Government support, investment in life sciences, an appetite for innovation, and regulatory pathways that enable companies to move quickly have contributed to significant development activity, particularly in oncology, cell and gene therapy, antibody-drug conjugates (ADCs), and bispecific antibodies.

That growth is increasingly connected to the global development landscape. By Q1 2026, China-based biotech companies accounted for nearly 30% of the global drug-development pipeline, with more than 1,200 novel candidates in clinical trials. Cross-border licensing and co-development are also becoming increasingly important routes for taking that innovation into global development.

The scale of those connections is significant. In 2025, the publicly disclosed value of outbound licensing transactions involving Chinese innovative drugs reached $135.7 billion, compared with $51.9 billion the previous year. Co-development partnerships with global pharmaceutical companies are also becoming part of that evolving landscape.

For global biotech and pharmaceutical companies, that creates a significant opportunity. Acquiring or licensing a promising molecule, however, is only the beginning. The real challenge is working out how to take an asset developed in China and move it successfully into a global development and registration pathway.

From Trial Destination to Source of Innovation

Personally, I’ve worked with China for around 20 years, and it has always been important, just for different reasons.

Earlier in my career, the decision about whether to include China in a clinical development program usually came down to two things: do you want to sell the drug there, and is there such a high prevalence or incidence of the disease that it would make little sense not to run the trial there?

If you were working in areas such as hepatitis or HCC, or various high-incidence cancers, for example, there was a very clear patient recruitment rationale. But it was still a big strategic decision because it could take more than a year to get a trial started, with numerous hurdles along the way.

The environment has changed unrecognizably. Regulatory reforms and accelerated pathways have moved China from amongst the slowest, to one of the fastest for early-stage clinical development activities. Meanwhile, discovery productivity has exploded, and China now leads the world in innovative new assets.

That changes the conversation for global drug developers.

Why Global Pharma Is Looking to China

For larger pharmaceutical companies, China represents an increasingly important source of potential pipeline augmentation.

There are a lot of molecules being developed, the science can be highly innovative, and valuations can be attractive in terms of upfront payments. For global pharmaceutical companies looking at strategies to replenish their pipelines, that makes China a very interesting place to look.

We can already see the international nature of this market through collaborations involving companies including GSK and Hengrui, Novartis and Argo Biopharma, AstraZeneca and CSPC Pharma, and Regeneron and Hansoh Pharma. The structures vary from global licensing and ex-China commercialization rights to broader co-development arrangements.

Oncology is a particularly important part of the story. There is still significant unmet need, but also considerable opportunity to innovate through new mechanisms of action and combinations. If you find an asset that works particularly well, there is an opportunity to make a real difference for patients.

This raises an important question: what happens once an early asset developed in China, purely with Chinese patients, is acquired or licensed for development elsewhere?

Bridging China-Originated Assets into Global Development

One pathway that has helped enable early development in China is the investigator-initiated trial, or IIT, pathway. It can allow investigators to initiate early-stage studies quickly and generate rapid proof of concept.

But if that asset is then licensed to a US biotech or another company with ex-China rights, the initial IIT evidence must be assessed against the requirements of authorities such as the FDA. Key considerations include whether the studies meet applicable GCP standards, whether the findings can be extrapolated to the intended US population, and whether differences in medical practice, ethnicity, or standard of care could influence outcomes.

The goal is not to disregard the work already completed or assume that studies conducted in China must be repeated. It is to determine what evidence is robust and usable, identify any remaining gaps, and choose the most appropriate way to address them. Some gaps may be resolved through real-world data or targeted bridging strategies, while others may require additional prospective clinical evidence. Understanding US and European regulatory expectations early can help teams avoid costly missteps.

From there, the focus shifts to designing the right development path. Simulation allows teams to explore how decisions around endpoints, sample size, patient characteristics, recruitment, and adaptive design could influence study outcomes before moving into execution. At MMS, we apply this approach through KerusCloud®, using virtual study scenarios and realistic synthetic patient populations to bring additional evidence into decisions about the studies still to come.

Getting the Data Right

A different challenge emerges when an asset moves between organizations. The original developer may retain the rights to an asset in China while another company owns the rights in the US or other international markets. Data may therefore need to move across different organizations, systems, vendors, and development environments. Further, sponsors should also be aware of Chinese requirements governing cross-border transfers of clinical and patient-level data, where applicable. This is precisely where our MMS biometrics, regulatory, and technology expertise intersect.

Standardizing and integrating that information creates a common foundation, but teams also need to be able to explore it as new clinical and development questions arise. When information is spread across clinical, operational, safety, and other datasets, reaching the underlying evidence can require specialist queries or bespoke outputs.

Datacise® brings these disparate sources into a harmonized environment where clinical and operational data can be reviewed and explored together. AI is also changing how teams can interact with those data. Ask the Data™, within Datacise®, enables clinicians and study teams to ask questions of validated study data in plain English, with structured answers that show the assumptions and logic applied and provide access to supporting subject-level evidence.

For acquired assets, this could be particularly relevant. The new development team may be asking questions that were never anticipated when the original studies were designed, so being able to interrogate existing evidence as those questions emerge can help inform the evolving development strategy.

Scientific and regulatory expertise remains central to that process. Accessible, well-structured data give statisticians, data scientists, clinicians, and regulatory specialists a stronger basis for examining the evidence, understanding its limitations, and deciding what it means for the program.

Regulatory Strategy and CMC Considerations

At the point when a company is deciding whether to acquire rights to an asset, it is primarily going to be looking at the fundamental data, the efficacy signals available at that point, and the potential market.

Regulatory due diligence also matters.

Particularly where a molecule has gone through the IIT pathway, you need someone to assess what has been done and establish whether everything is in order for the next stage of development.

There is a CMC component as well. Where is the product being manufactured? What is the approach to manufacturing? What will be required around GMP quality and compliance as the program moves into global development?

None of that necessarily changes whether the molecule itself is interesting, but it does influence what needs to happen next and where additional work may be required.

That assessment increasingly extends beyond clinical and CMC considerations to the wider geopolitical and regulatory environment. On October 16, 2026, China proposed tighter controls on the export and transfer of 40 strategic technologies, including several relevant to biopharma, while an October 22 US Treasury proposal would extend outbound investment restrictions to biotechnology. Following the BIOSECURE Act enacted in December 2025, these developments add complexity to cross-border investment, joint ventures, and technology transfer. They do not, however, amount to a blanket ban on licensing individual drug assets, although deal structures and associated technology transfers will require closer scrutiny.

What Comes Next?

I don’t see the current pace of Chinese drug discovery changing. If anything, it could accelerate.

AI-augmented discovery is happening globally, and China is no different. That creates the potential for an even more productive discovery engine, with more assets progressing through preclinical and early clinical development and entering the broader development funnel.

At the same time, I think we will continue to see Chinese companies thinking more globally themselves. Some will choose international licensing and co-development partnerships, while others may decide to take their own programs further through global development.

For sponsors looking at China-originated assets, the opportunity is significant. The value of a China-originated asset is not determined by its early clinical promise alone. It also depends on how efficiently that promise can be translated into globally acceptable evidence. This is where early regulatory planning, statistical strategy, data readiness, and CMC considerations can materially influence development timelines, investment decisions, and ultimately the value of the asset.

China has already become an important engine of pharmaceutical innovation. The opportunity now lies in translating that innovation into robust global development programs that can successfully advance promising assets toward patients around the world.

Case Study Card

See how a China-originated asset progressed toward US IND readiness. Explore how MMS identified critical regulatory and data gaps and helped an emerging biopharma navigate the transition from a China-focused development package to a US IND submission package.

Suggested For You

perspectives

November 3rd, 2026

FAST-EU and the European Biotech Act: What Regulatory Change Means for Clinical Trial Strategy

perspectives

October 22nd, 2026

The Evolving Role of Tau Imaging in Alzheimer's Disease

perspectives

October 7th, 2026

AI's Impact on Small Biotechs: Why Better Decisions, Not Just Faster Processes, Will Define Success

perspectives

September 29th, 2026

Getting to First-in-Human Faster: What FDA’s New IND Pilot and NAMs Shift Mean for Sponsors

perspectives

September 21st, 2026

From Data to Decisions: Evaluating Bayesian Dynamic Borrowing Before Your Trial Begins

perspectives

September 11th, 2026

Navigating the Future of Clinical Trial Transparency: Balancing AI-Driven Anonymization with Human Oversight 

perspectives

September 3rd, 2026

From Signal to System: FDA Approval Does Not Mean Treatment Can Begin the Next Morning

perspectives

August 27th, 2026

Risk-Based Data Management: Moving Beyond Traditional Data Cleaning

perspectives

August 17th, 2026

From Signal to System: The Evidence Questions Psychedelic Therapies Must Answer

perspectives

August 11th, 2026

The Race to Faster Drug Development: A Quicker On-Ramp Doesn’t Help If You’re Headed the Wrong Way 

perspectives

August 7th, 2026

UK Clinical Trial Transparency Changes for Phase I Studies: What Sponsors Need to Know

perspectives

July 31st, 2026

FDA Orphan Drug Designation Requirements: Key Mistakes to Avoid